In an article published in DDN, Taconic's Dr. Megan MacBride comments on the advantages of using syngeneic tumor models in certain preclinical research applications. While syngeneic models have existed for more than seventy years, they still have relevant applications in current research studies. Given their unique ability to facilitate the study of tumor-immune system interactions and immunotherapy efficacy, syngeneic tumor models will continue to serve as a workhorse of immuno-oncology research:
"Sometimes, the solution to a challenge is not the newest advancement but a tried-and-true approach that's proven effective for decades. Such is the case with the use of syngeneic tumor models in certain preclinical research applications. Used for more than 70 years, syngeneic mouse models are employed extensively in early-stage drug discovery and have become a workhorse for one of the fastest-growing areas of research: immuno-oncology. These well-documented models are transforming how investigators approach novel therapies, especially immunotherapies."
Read more about syngenic models and their specific uses by viewing the complete article at: DDN-News.com
"Sometimes, the solution to a challenge is not the newest advancement but a tried-and-true approach that's proven effective for decades. Such is the case with the use of syngeneic tumor models in certain preclinical research applications. Used for more than 70 years, syngeneic mouse models are employed extensively in early-stage drug discovery and have become a workhorse for one of the fastest-growing areas of research: immuno-oncology. These well-documented models are transforming how investigators approach novel therapies, especially immunotherapies."